10 May saw the return of the Annual Network Meeting and, with 2017 marking the network’s 10th anniversary, it was indeed a very exciting and special event. Over 260 attendees from across the network joined us in the De Vere Grand Connaught Rooms in London.
The meeting began with a real appreciation of everything the ECMC network has done, and will continue to do in the years to come, with Sir Harpal Kumar (CRUK) and Dr Louise Wood (DoH) highlighting the network’s impressive achievements from the past decade, and trial spotlight talks from ICR and Edinburgh.
Describe the PATRIOT trial and the anticipated patient benefit.
The PATRIOT study is a multicentre ECMC Combinations Alliance Phase I study looking at the ATR inhibitor AZD6738 as a monotherapy in advanced solid tumours, and in combination with palliative radiotherapy. ATR inhibitors are a new class of anticancer therapy and there is significant evidence that they may provide tumour-selective radiosensitisation.
We discuss with Professor Tim Meyer (Joint-Lead for UCL ECMC ), the set-up of routine molecular diagnostics at UCL ECMC which is now offered to all patients who are eligible to enrol in early phase clinical trials at the NIHR/Wellcome UCH Clinical Research Facility (CRF). This innovative approach offers a sustainable and more cost-effective solution to the rising costs of screening patients for trials of molecularly stratified agents.
Southampton ECMC specialises in evaluation of how different components of the immune system modify haematological and solid tissue malignancies. This is a relatively new field of investigation with novel tools, techniques and assays being developed regularly. The pace of change poses substantial challenges in working with these assays in a regulated environment. The Southampton ECMC analytical team regularly validates research assays for immunological monitoring of clinical trials. Here Dr Ruth Challis talks to us about the validation of new assays for use in phase I trials.
Leukaemia and Lymphoma Research (LLR) and the National Amyloidosis Centre (NAC) based at the Royal Free Hospital in London are jointly funding a new clinical trial that will use a completely new method of preparing patients with AL-amyloidosis for autologous stem cell transplantation.
AL-amyloidosis (AL-A) is a serious haematological condition related to multiple myeloma and is characterised by the deposition of AL-amyloid protein fibrils in various organs such as the heart, liver, spleen and kidneys causing severe impairment of function.
Dr Tim Yap and his colleagues updated the ECMC Annual Network meeting on the exciting drug combination development trials across the ICR ECMC which he summarises here for ECMC-Connect.
At July’s training day for nurses, Anne Croudass and Sandie Wellman presented on administering novel agents in early phase cancer trials and a summary of their guidance is presented below.
Many of the roles and responsibilities of staff working in early phase trials mirrors the activity of other research staff working in any field of clinical research. One aspect of the role of the early phase research nurse is relatively unique and that is the administration of novel agents to patients.